AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application.

IN THE CLAIMS:

1. (Previously presented) An isolated, synthetic or recombinant χ-conotoxin peptide comprising the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pyroglutamate(pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion;

or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof.

2. (Previously presented) The peptide according to claim 1 consisting of the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaal is a N-terminal pGlu or DpGlu residue; and Xaa2 is Asn or a deletion;

or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof.

3. (Previously presented) The peptide according to claim 1 wherein said sidechain comprises replacement of Tyr with 4-methoxy tyrosine and/or replacement of Pro with 4-hydroxyproline.

4. (Previously presented) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 4
Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Xaa5	SEQ ID NO. 5
Xaal Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 6
Xaal Asn Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 7

Xaal Asn Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 8

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 9

where Xaal refers to pyroglutamic acid, Xaa3 refers to 4-hydroxyproline, Xaa4 refers to 4-methoxy tyrosine, Xaa5 refers to D-cysteine and-OH indicates a free acid C terminal.

5. (Previously presented) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 10

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 11

where Xaal refers to D-pyroglutamic acid, Xaa3 refers to 4-hydroxyproline and-OH indicates a free acid C terminal.

6. (Previously presented) A composition comprising the peptide of any one of claims 1 to 5 together with pharmaceutically acceptable carrier or diluent.

7. (Original) The composition of claim 6 further comprising one or more other active agents.

8. (Currently amended) ~~Use of the χ-conotoxin peptide of any one of claims 1 to 5 as an inhibitor of neuronal noradrenaline transporter, and in~~ A method for the treatment or prophylaxis of diseases or conditions in a mammal in relation to which the inhibition of neuronal noradrenaline transporter is associated with effective treatment or prophylaxis, comprising administering to the mammal an effective amount of the χ-conotoxin peptide of any one of claims 1 to 5.

9. (Currently amended) ~~Use according to~~ The method of claim 8, ~~in the prophylaxis or treatment of~~ wherein the diseases or conditions ~~of~~ comprise the diseases or conditions of the urinary or cardiovascular systems, or mood disorders, or ~~in the treatment or control of~~ acute, chronic and/or neuropathic pain, migraine or inflammation.

10. (Currently amended) ~~Use according to claim 9 in the treatment of~~ The method of claim 11, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, nerve damage, inflammatory pain and peripheral nerve associated pain.

11. (Currently amended) A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases or mood disorders or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation in a mammal comprising administering to [[a]]the mammal an effective amount of an isolated, synthetic or recombinant χ-conotoxin peptide of any one of claims 1-5~~having the ability to inhibit neuronal noradrenaline transporter, wherein said χ-conotoxin peptide comprises the following sequence of amino acids:~~

~~Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3~~

~~where Xaa1 is a N-terminal pGlu or DpGlu residue; and Xaa2 is Asn or a deletion;~~

~~or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt or prodrug thereof~~.

12. (Original) The method of claim 11 wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of the conditions, diseases or disorders.

13. (Currently amended) ~~Use of the peptide of claim 1 in the manufacture of a medicament~~ A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases, or mood disorders, or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation in a mammal comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant χ-conotoxin peptide of claim 1.

14. (Previously presented) The method of claim 11 wherein said sidechain modification comprises replacement of Tyr with 4-methoxy tyrosine and/or replacement of Pro with 4-hydroxyproline.